The purpose of this research was to investigate the role of Vav3 oncogene in human prostate cancer. We found that expression of Vav3 was significantly elevated in androgen-independent LNCaP-AI cells in comparison with that in their androgen-dependent counterparts LNCaP cells.
INTRODUCTION
Compelling data show that the elevated androgen receptor (AR) activity and PI3K-Akt signaling play an important role in prostate cancer development and progression (1) (2) (3) (4) . The PI3K-Akt pathway is cell growth and survival pathway for human cancers. Elevated PI3K-Akt signaling, such as mediated by PTEN deletion and mutation, contributes to prostate cancer development and progression. Prostate-specific deletion of murine PTEN, a tumor suppressor gene that shuts off PI3K-Akt signaling, induces the prostatic intraepithelial neoplasia lesions, which later progress to invasive prostate cancer in mice (5). Multiple growth factors and cytokines, including epidermal growth factor (EGF), signal through the PI3K-Akt pathway and inappropriately activates AR in prostate cancer cells, which can be accomplished by direct AR phosphorylation by active Akt (6-8). PI3K-Akt signaling can also induce phosphorylation and inactivation of GSK3β, resulting in an increased nuclear level of β-catenin. Consequently, coactivator β-catenin enhances AR activity to stimulate prostate cancer cell growth and survival (9, 10). Studies from our laboratory as well as others demonstrate that elevated PI3K-Akt signaling is critical for androgen-independent growth of human prostate cancer cells (11). It is noteworthy, however, that an elevation of Akt phosphorylation is observed in 45.8% of prostate cancer specimens (12) and a loss of or reduced PTEN protein expression occurs in approximately 30% of human prostate cancers (13, 14) , suggesting the presence of other mechanisms that activate PI3K-Akt signaling in prostate cancer.
Vav gene is an oncogene identified in cell transformation experiments (15) . Vav family proteins include three members (Vav1, Vav2, and Vav3) in mammalian cells (16) (17) (18) . Vav1 is primarily expressed in hematopoietic lineages, while Vav2 and Vav3 are more ubiquitously expressed (19) . Vav proteins share a common structure, including a N-terminal calponin homology (CH) domain involved in Ca +2 mobilization and transforming activity, an acidic region containing three regulatory tyrosines, a Dbl homology (DH) domain with a conserved region that promotes the exchange of GDP for GTP on Rac/Rho GTPases, a pleckstrin homology (PH) domain binding to PIP 3 that enables its movement to the inner face of the plasma membrane, two Src-homology 3 (SH3) domains interacting with proteins containing proline-rich sequences, and a Src-homology 2 (SH2) domain interacting with the proteins containing phosphorylated tyrosines (20, 21 Grb2, and PLC-γ, leading to alteration in cell morphology and cell transformation (23).
Similarly, overexpression of Vav3 leads to PI3K activation and focus formation in NIH3T3 cells.
Vav3-induced cell transformation can be blocked by overexpression of PTEN or PI3K inhibitor LY294002 (24). However, the role of Vav3 in human cancer has not been described. androgen-independent human prostate cancer cell lines (PC3, DU145, and 22RV1) (Fig. 1A) .
To determine the potential role of Vav3 in prostate cancer, we evaluated Vav3 expression in surgical specimens of human prostate cancer by immunohistochemistry (IHC). Eighty-two tumor tissues and 10 normal tissues from patients of 38-87 year-old were analyzed ( Table 1) .
Vav3 protein was detected in 26 tumor tissues (32%). All normal prostate tissues showed negative immunoreactivity for Vav3. As shown in Fig. 1B , Vav3 protein was located in the tumor epithelium but not stroma or normal prostate tissues. A significance difference was found for Vav3 gene positive (n=26) and negative (n=56) prostate cancer specimens (P < 0.001) using binomial method and log link function. A retrospective power analysis was carried out to determine the association of Vav3 expression and Gleason score and showed that the study had approximately 52% power to detect a significant trend given the observed data, assuming a significance level of alpha=5%. Therefore, our sample size is not large enough to demonstrate the association between Vav3 expression and Gleason score in prostate cancer. (Fig. 3A) . Overexpression of Vav3 or Vav3* did not alter AR expression in these cells (Fig. 3B) . We found that overexpression of constitutive active Vav3* significantly stimulated cell growth in the absence of androgen. On day 6, the OD reading, which reflects the cell density, in wells containing LNCaP-Vav3* cells, was 1.6 fold higher than those containing LNCaP-HEF cells (Fig. C) . Overexpression of wild type Vav3 potentiated growth stimulatory effects of EGF (Fig. 3D) . In the cultures containing 1.6 ng/ml of EGF, the density of LNCaP- 
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The DH domain of Vav3 is responsible for activation of AR
To dissect the functional domain of Vav3 involved in AR activation, we generated truncated constructs of Vav3* with either deletion of the DH domain (Vav3*-∆DH) that has GEF activity or the SH domain that has adaptor activity (Vav3*-∆SH) (Fig. 7A) . We found that the ARE promoter activity was moderately enhanced in cells cotransfected with Vav3 and was significantly elevated in cells cotransfected with Vav3* in Hela cells (Fig. 7B) were purchased from Invitrogen.
MATERIALS AND METHODS
Reagents
Anti-Vav3 antibody from Upstate Biotechnology (Charlottesville, VA) was used for IHC analysis. We also generated our custom anti-Vav3 antibody from the C-terminus of Vav3 peptide sequence (CMELVEYYKHHSLKEGFRT). We determined Vav3 expression from normal mouse prostate tissues and LNCaP cells and no non-specific band was detected by this antibody.
Wild type Vav3 showed a 98 kD band and Vav3* showed a 75 kD band. Our custom Vav3
antibody was used for western blot analysis in this study.
Cell culture
The human prostate adenocarcinoma cell lines (LNCaP, PC-3, DU145, and 22Rv1) and cervical carcinoma cell line Hela were obtained from ATCC (Rockville, MD) and maintained in RPMI-1640 medium supplemented with 10% FBS (complete medium) at 37 o C in 5% CO 2 . The androgen-independent LNCaP-AI cells were derived from LNCaP cells by long-term culture of the latter in RPMI-1640 medium supplemented with 10% charcoal/dextran-treated FBS (stripped medium) (25). LNCaP-AI cells were maintained in stripped medium.
Plasmids
The construction and structure of pBEF-Vav3, pHEF-Vav3*, and control vector pHEF were detailed in our previous studies (24). Vav3* is a constitutive active form of Vav3 due to the CH domain and acidic region deletion at N-terminus (Fig. 7A) . PSA(-4. 
Cell growth assay
Tumor cell growth was estimated by the MTT assay as previously described (25). Briefly, LNCaP and LNCaP-AI cells were seeded into 96-well cell culture plates at a density of 5x10 3 cells/well in stripped medium. After incubation in 5% CO 2 at 37°C overnight, the cells were treated with various concentration of drugs in stripped medium for 5 days. At the end of incubation, 20 ul of MTT (2.5 mg/ml in PBS) was added to each well, and the cells were further incubated for one hour at 37°C to allow complete reaction between the dye and the enzyme mitochondrial dehydrogenase in the viable cells. After removal of the residual dye and medium, 100 ul of dimethylsulfoxide was added to each well, and the absorbance at 570 nm was measured using BMG microplate Reader (BMG Labtech, Inc., Durham, NC).
Western blot analysis
Western blot analysis was performed as previously described (25). Briefly, aliquots of samples with the same amount of protein, determined using the Bradford assay (BioRad, Hercules, CA),
were mixed with loading buffer (final concentrations of 62.5 mM Tris-HCl, pH 6.8, 2.3% SDS, 100 mM dithiothreitol, and 0.005% bromophenol blue), boiled, fractionated in a SDS-PAGE, 
